Analysts’ Top Healthcare Picks: United Therapeutics (UTHR), Sino Biopharmaceutical (SBMFF)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on United Therapeutics (UTHR) and Sino Biopharmaceutical (SBMFF) with bullish sentiments.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
United Therapeutics (UTHR)
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on United Therapeutics, with a price target of $660.00. The company’s shares closed last Wednesday at $569.01.
According to TipRanks.com, Fein is a 5-star analyst with an average return of
United Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $656.85, representing a 15.2% upside. In a report issued on May 7, Wells Fargo also upgraded the stock to Buy with a $738.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Sino Biopharmaceutical (SBMFF)
In a report released today, Mark Kong CFA from DBS initiated coverage with a Buy rating on Sino Biopharmaceutical and a price target of HK$6.50. The company’s shares closed last Monday at $0.69.
According to TipRanks.com, CFA is ranked #4646 out of 12240 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sino Biopharmaceutical with a $1.08 average price target.
Read More on UTHR:
Disclaimer & DisclosureReport an Issue
- United Therapeutics says TETON-1 study published in NEJM
- United Therapeutics cleared by FDA to proceed with UHeart clinical trial
- United Therapeutics, Varda Space Industries team on use of microgravity
- United Therapeutics to present positive data of treprostinil in IPF
- United Therapeutics price target lowered to $516 from $519 at Morgan Stanley
